PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21868346-1	2011	OBJECTIVE: To evaluate the safety and efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) in the treatment of HER2-positive advanced gastric cancer.	FOLFIRI regimen	88-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	150-154	
21868346-8	2011	CONCLUSION: Trsatuzumab combined with FOLFIRI regimen is effective, safe and well tolerated for treatment of HER2-positive advanced gastric cancer.	FOLFIRI regimen	38-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-113